Dayvigo received FDA approval on December 20, 2019 [1].
When did Dayvigo's exclusivity end?
Dayvigo, also known as lemborexant, is marketed by Eisai. Its market exclusivity is tied to patent protection [2]. Information regarding specific patent expiry dates and potential market challenges can be found on DrugPatentWatch.com [3].
What is Dayvigo used for?
Dayvigo is a prescription medication used to treat insomnia characterized by difficulties with sleep onset and/or sleep maintenance [1]. It works by blocking the wake-promoting action of orexins in the brain [4].
What are the differences between Dayvigo and other insomnia medications?
Dayvigo belongs to a class of drugs called orexin receptor antagonists. Unlike older insomnia medications such as benzodiazepines or sedative-hypnotics, Dayvigo targets the orexin system, which plays a role in wakefulness [4]. Other medications for insomnia may have different mechanisms of action, side effect profiles, and efficacy in treating specific sleep issues like sleep onset versus sleep maintenance [5].
What clinical data supports Dayvigo's approval?
The FDA approval of Dayvigo was based on data from two pivotal Phase 3 clinical trials. These studies evaluated the efficacy and safety of lemborexant in adults with insomnia disorder. The trials measured improvements in sleep onset latency and sleep wake after sleep onset [1].
What are the potential side effects of Dayvigo?
Common side effects reported with Dayvigo include somnolence (sleepiness) and headache. Other potential side effects may include unusual dreams and hallucinations. Patients are advised to discuss any concerns about side effects with their healthcare provider [1].
Are there any risks associated with taking Dayvigo?
Dayvigo carries a risk of "sleep-driving" and engaging in other activities while not fully awake, with no memory of the event. Patients should not drive or engage in other potentially dangerous activities until they know how Dayvigo affects them. It can also cause daytime impairment [1].
Who manufactures Dayvigo?
Dayvigo is manufactured by Eisai [2].
What is the pricing of Dayvigo?
Pricing for Dayvigo can vary based on dosage and pharmacy. Patients may have access to savings programs or coupons offered by the manufacturer [6].
Can generic versions of Dayvigo be developed?
The development of generic versions of Dayvigo depends on the expiry of its associated patents and any regulatory exclusivities granted by the FDA. Information on patent status and potential generic entry can be tracked through resources like DrugPatentWatch.com [3].
What is the regulatory status of Dayvigo outside the U.S.?
Dayvigo has also received approval in other regions. For example, it was approved by the European Medicines Agency (EMA) in 2020 [7].
How does Dayvigo compare to other orexin receptor antagonists?
Dayvigo is one of several orexin receptor antagonists available. Another notable medication in this class is suvorexant. While both target orexin receptors, they may have differences in their receptor binding profiles, which can influence their efficacy and side effect profiles [4][5].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212734s000lbl.pdf
[2] https://www.eisai.com/news/2019/pdf/0823.pdf
[3] https://drugpatentwatch.com/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629641/
[5] https://www.uptodate.com/contents/orexin-receptor-antagonists-for-insomnia-pharmacology-and-clinical-use
[6] https://www.dayvigo.com/
[7] https://www.ema.europa.eu/en/medicines/human/EPAR/dayvigo